Medicare Part D Spending in 2019 Lower Than Expected Because Of Rebates
Executive Summary
Medicare Trustees Report highlights importance of rebates in Part D but does not address potential changes to system; charts detail the growing impact rebates are expected to have in coming years.
You may also be interested in...
HHS Rebate Reform: An Air Of Inevitability In Stakeholder Comments
Manufacturers, pharmacy benefit managers and insurers weigh in on the Trump administration’s most significant drug pricing action to date – the HHS Office of Inspector General's proposed rule aimed at eliminating rebates.
HHS Rebate Plan A Leap Of Faith? Lower Costs Hinge On Drug Firm, Plan Response
HHS seeks input on how stakeholders might adjust to a system without rebates and requests comments on three actuarial reports that attempt to project the financial impact of the change.
Medicare Part D Spending Projected To Decline in 2018 As Rebates Increase
Part D plans project rebates will increase to 25.3% of total drug costs in their bids for the 2018 benefit year, the recently-released Medicare Trustees Report notes.